Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists decode genetic clues in rare bone marrow cancer

NCT ID NCT05710211

Knowledge-focused Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how specific genetic changes (ASXL1 mutations) affect the course of myelofibrosis, a rare bone marrow cancer. Researchers will analyze blood and bone marrow samples from 50 adults to identify different patterns of these mutations. The goal is to better predict how the disease will progress and guide future treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Apr 2031

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (age ≥18 years), * Affiliated to the national social security system, * ASXL1 mutated primary or secondary myelofibrosis, * Signed the consent to participate in the study, * Included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM). Exclusion Criteria: * Patient with another active hematological disease or cancer at the time of diagnosis, * Person subject to legal protection scheme or incapable of giving consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myelofibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myelofibrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP Hôpital Saint Louis

    NOT_YET_RECRUITING

    Paris, 75010, France

  • CH Cholet

    NOT_YET_RECRUITING

    Cholet, France

  • CH de Cornouaille

    NOT_YET_RECRUITING

    Quimper, France

  • CH de Vannes

    NOT_YET_RECRUITING

    Vannes, France

  • CHRU Brest

    NOT_YET_RECRUITING

    Brest, France

  • CHRU Tours - Hôpital Bretonneau

    RECRUITING

    Tours, France

  • CHU Angers

    RECRUITING

    Angers, France

  • CHU Henri MONDOR

    RECRUITING

    Créteil, 94010, France

  • CHU Lyon

    RECRUITING

    Pierre-Bénite, 69495, France

  • CHU Nantes

    NOT_YET_RECRUITING

    Nantes, France

  • CHU de Bordeaux

    RECRUITING

    Pessac, 33604, France

  • Hôpital Bicêtre

    RECRUITING

    Paris, France

  • Institut Paoli Calmettes

    RECRUITING

    Marseille, 13009, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.